Late Breaking News
Abstracts of exceptional originality and importance, completed after May 4, 2023 may be considered for oral presentation in the Late Breaking News Session if submitted by July 24, 2023 directly by e-mail to firstname.lastname@example.org
For abstract requirements and format please follow the same guidelines as noted below for the regular abstract-submission.
Name and Affiliations of all authors should be disclosed including any COI’s.
Decisions will be sent by July 31, 2023.
These abstracts will not be included in the digital issue of Abstracts.
|Inborn errors of metabolism in adults||Dietetics and nutrition|
|Disorders of fatty acid oxidation and ketone body metabolism||Glycosylation disorders/CDG, protein modification disorders|
|Novel diagnostic/laboratory methods including omics||Phenylketonuria|
|Mitochondrial disorders||Neurotransmitter and creatine related disorders|
|Innovative therapies such as RNA-based therapy, gene therapy and regenerative medicine||Amino acid disorders|
|Disorders of purines, pyrimidines, nucleic acids and porphyrias||Disorders of vitamins, cofactors and trace elements|
|Metabolic myopathies||Urea cycle disorders|
|Peroxisomal, sterol, bile acid, lipid and lipoprotein metabolism||New Diseases|
|Newborn screening||Organic acidurias|
|Lysosomal disorders||Clinical studies, patient reported outcome measures, outcome|
|Nursing in metabolic disorders|
GUIDELINES FOR ABSTRACT-SUBMISSION
Abstracts have to be submitted exclusively online.
Deadline for submission is extended to May 4, 2023.
Authors can submit their abstracts for oral presentation, poster presentation or both.
There is no difference in submission of abstracts for oral or poster presentations. Submitted abstracts can only be modified prior to the submission deadline.
The presenting author must be listed first and must be the author that submits the abstract.
- Each contribution must relate to one of the featured conference topics.
- Each abstract can only be submitted to one featured conference topic.
- Abstracts must be submitted and presented in English.
The abstract is limited to 2,000 characters including spaces.
- Abstracts must be structured as follows: Background, Case Study / Methods, Results, Discussion/Conclusion
- The title should be written in standard sentence style with lower case letters (except first word, names, human gene names [always upper-case letters & italics], etc.).
- The text should be grammatically suitable for publication.
- Special characters can be included during submission.
- Non-standard abbreviations must be defined in the text.
- Drugs must be mentioned by generic names, not trade names.
- Abstracts must not be used to promote specific drugs, instruments etc.
Submitted abstracts must provide results and not announcements; stating that “Findings will be discussed…” or similar is not acceptable.
The usage of special formatting should be limited. The correct replication in all media cannot be guaranteed.
The presenter is responsible for compliance with data protection, copyrights, ethical regulations and laws.
- The abstract should be novel. It is acceptable to submit abstracts related to information already reported at another conference or in a journal provided that new information will also be presented. The authors should declare this during submission and make clear the new information that will be presented. Please tick the appropriate box “Parts of the data have been published previously”.
- To secure anonymity of the review process, names and locations should not be disclosed in the abstract.
Accepted abstracts will be published in a dedicated on-line supplement of the JIMD (Journal of Inherited Metabolic Disease). Therefore, all accepted abstracts will be reviewed for typing errors and will be corrected, if necessary.
- Authors’ fees or royalties cannot be claimed.
- All listed authors have to consent to the abstract text as well as to their publication in all congress media.
- Conflicts of interest through commercial benefits have to be disclosed.
In general, the SSIEM does not accept abstracts from companies. Abstracts must not be used to promote specific drugs, instruments etc. The presenter is responsible for compliance with data protection, copyrights, ethical regulations and laws. In cases where there is collaboration between companies and researchers from non-profit organizations, the work might be suitable for an abstract. Such an abstract will undergo standard selection procedures provided that conflicts of interests are clearly stated in detail. If the abstract is selected for an oral or poster presentation the presentation must submitted and given by the collaborating researcher that is not employed by the company.
All submitted abstracts will be reviewed by several international experts.
Evaluation criteria are: Aim(s) and objective(s), materials and methodology, results and conclusions.
Abstracts that contain formal errors (multi-topic submission, not anonymised) will be rejected.
Abstracts may be selected for one of the following presentation forms:
- Late Breaking News Session on Friday morning
- Parallel Free Communications Sessions on Wednesday and Thursday
- Poster displayed throughout the Conference
- e-Poster available throughout the Conference
E-mail notifications about acceptance or rejection will be sent to the presenting author subsequent to the
reviewing process by Mid-June, 2023.